BiotechTube

sofosbuvir/velpatasvir

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Thalassemia

Conditions

Thalassemia, Hepatitis C

Trial Timeline

May 1, 2017 → Aug 6, 2018

NCT ID
NCT03032666

About sofosbuvir/velpatasvir

sofosbuvir/velpatasvir is a approved stage product being developed by Gilead Sciences for Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03032666. Target conditions include Thalassemia, Hepatitis C.

What happened to similar drugs?

6 of 16 similar drugs in Thalassemia were approved

Approved (6) Terminated (2) Active (10)
✅DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
🔄deferasiroxNovartisPhase 3
🔄ICL670 + deferoxamineNovartisPhase 3
✅Zoledronic AcidNovartisApproved
✅DeferasiroxNovartisApproved
🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03235154ApprovedCompleted
NCT03032666ApprovedCompleted

Competing Products

20 competing products in Thalassemia

See all competitors
ProductCompanyStageHype Score
LuspaterceptMerckPhase 2
35
luspaterceptMerckPhase 2
35
ACE-536MerckPhase 2
42
luspaterceptMerckPhase 2
35
DeferasiroxNovartisApproved
43
Blood sampleNovartisPre-clinical
26
deferasirox + placeboNovartisPhase 2
35
Zoledronic acid + PlaceboNovartisPhase 2/3
34
deferasiroxNovartisApproved
35
deferasiroxNovartisPhase 3
40
ICL670 + deferoxamineNovartisPhase 3
40
ruxolitinibNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)NovartisPhase 2
35
Zoledronic AcidNovartisApproved
43
DeferasiroxNovartisPhase 2
27
DeferasiroxNovartisApproved
35
Deferasirox + Deferoxamine (DFO)NovartisPhase 2
27
DeferasiroxNovartisPhase 1
29
DeferasiroxNovartisPhase 3
40